Former President Biden's Prostate Cancer Diagnosis Reignites Debate Over Annual Screenings

Former President Biden's recently diagnosed aggressive prostate cancer, which has spread to his bones, has reignited the debate about who should receive annual screenings for signs of the disease. Prostate cancer, the second most common cause of cancer deaths for men, kills 35,000 annually. While some experts argue that annual screenings are crucial, others claim that the benefits may not outweigh the risks, particularly for men aged 70 and older.

Key Takeaways:

• The U.S. Preventive Services Task Force recommends against screening in men 70 years and older, citing potential harms such as false-positive results, overdiagnosis, and treatment complications.
• The American Cancer Society recommends that men discuss screening with their provider starting at age 40 for those with a family history of prostate cancer, at age 45 for African American men with a first-degree relative diagnosed at an early age, and age 50 for those at average risk.
• The American Urological Association's guidelines are the most aggressive, recommending screening beginning at age 40 for men at high risk and regular screening every two to four years for people aged 50 to 69.
• The Prostate Cancer Foundation recommends increased screening, citing advanced treatment options and minimally invasive surgery.
• Former President Biden's cancer has a Gleason score of 9, indicating an aggressive form of the disease that has spread to his bones.
• His treatment path may involve hormone therapy to block testosterone production, which can extend life but typically includes significant side effects.
• Prostate cancer specialists note that the prognosis for someone with metastatic prostate cancer that has spread to the bone can range from three to five years, though some patients can live longer.

Statistics:

• 35,000 men die from prostate cancer annually in the United States.
• The Gleason score is a grading system for prostate cancer, rating 0-10; Biden's cancer has a score of 9, indicating an aggressive form.
• The hormone therapy to block testosterone production in prostate cancer patients typically includes side effects such as fatigue, hot flashes, cognitive issues, weight gain, loss of libido, lower bone density, and risk of fractures.
• Three to five years is the average life expectancy at diagnosis for someone with metastatic prostate cancer that has spread to the bone.

Sources:

• Washington Post article featuring experts from Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, and Johns Hopkins University.
• American Urological Association guidelines on prostate cancer screening.
• American Cancer Society recommendations on prostate cancer screening.
• U.S. Preventive Services Task Force recommendation against screening in men 70 years and older.
• Prostate Cancer Foundation guidelines on increased screening.
• Biden's office statement on his prostate cancer diagnosis.